Salicylamide
Specifications
65-45-2CAS Number
200-609-3EC Number
2-hydroxybenzamideIUPAC Name
C7H7NO2Chemical Formula
137.14 g/molMolecular Weight
salicylamide; 2-Hydroxybenzamide; 65-45-2; o-Hydroxybenzamide; 2-Carbamoylphenol; Benzamide, 2-hydroxy-; Salicylic acid amide; 2-Carboxamidophenol; Algiamida; Panithal; Oramid; Urtosal; Acket; Amidosal; Dolomide; Dropsprin; Liquiprin; Morsarinas; Raspberin; Saliamid; Saliamin; Salizell; Serramida; Algamon; Allevin; Anamid; Novecyl; Salicim; Salipur; Salrin; Salymid; Afko-Sal; Amid-Sal; Salicilamida; Benzamide, o-hydroxy-; Salicilamide; Salicylamidum; Cidal; Samid; DTXSID3021726; H.P. 34; SR 4326; Benzoic acid, 2-hydroxy-, amide; NSC-3115; EM8BM710ZC; DTXCID501726; CHEBI:32114; RefChem:6211; N02BA05; 200-609-3; Benesal; Salamid; Flarpirina; Andasol; Eggosalil; Salamide; MFCD00007978; 2-Hydroxy-benzamide; Amid kyseliny salicylove; OHB; NSC 3115; CHEMBL27577; MLS000069486; NCGC00091414-02; SMR000046394; Salizell (VAN); Benesal (VAN); Salicilamide [DCIT]; Salicilamide [Italian]; Salicylamidum [INN-Latin]; CAS-65-45-2; Salicilamida [INN-Spanish]; CCRIS 6045; HSDB 227; Amid kyseliny salicylove [Czech]; EINECS 200-609-3; UNII-EM8BM710ZC; BRN 0742439; Salicylamid; AI3-03454; hydroxy benzamide; dihydroxybenzalamine; Salicylamide [USP:INN:BAN:JAN]; Salicylamide, 99%; Spectrum_000946; Salicylamide (Standard); Opera_ID_1684; Spectrum2_001312; Spectrum3_000564; Spectrum4_000499; Spectrum5_001032; SALICYLAMIDE [MI]; WLN: ZVR BQ; SALICYLAMIDE [INN]; SALICYLAMIDE [JAN]; EC 200-609-3; SALICYLAMIDE [HSDB]; NCIOpen2_001127; SALICYLAMIDE [VANDF]; Oprea1_069894; SCHEMBL21646; BSPBio_001948; KBioGR_001017; KBioSS_001426; SALICYLAMIDE [MART.]; 4-10-00-00169 (Beilstein Handbook Reference); Deferasirox Benzamide Impurity; DivK1c_000858; SALICYLAMIDE [USP-RS]; SALICYLAMIDE [WHO-DD]; SCHEMBL162829; SCHEMBL875217; SPECTRUM1500532; Salicylamide (JAN/USP/INN); SPBio_001403; benzenecarboxamide, 2-hydroxy-; orb1224330; orb1311036; SCHEMBL1975862; SCHEMBL4116744; SCHEMBL10915695; SCHEMBL11516367; SCHEMBL29384763; HMS502K20; HY-B0811R; KBio1_000858; KBio2_001426; KBio2_003994; KBio2_006562; KBio3_001448; NSC3115; NINDS_000858; HMS1920P14; HMS2092G15; HMS2232E07; HMS5085G18; Pharmakon1600-01500532; component of Tolagesic (Salt/Mix); HY-B0811; MSK11195; SALICYLAMIDE [USP MONOGRAPH]; Tox21_111129; Tox21_201944; Tox21_302801; BBL016007; BDBM50056900; CCG-39250; EBC-03127; NSC757318; s6404; SBB058584; STK301812; AKOS000120983; Tox21_111129_1; CS-7630; DB08797; FS27782; NSC-757318; IDI1_000858; NCGC00091414-01; NCGC00091414-03; NCGC00091414-04; NCGC00091414-05; NCGC00091414-07; NCGC00256376-01; NCGC00259493-01; 287492-04-0; DS-16216; Salicylamide 100 |Ig/mL in Acetonitrile; Salicylamide, puriss., >=99.0% (T); SY009157; SBI-0051509.P003; DB-269424; Salicylamide 100 microg/mL in Acetonitrile; EU-0000058; NS00006293; ST45061688; EN300-18542; D01811; F85552; AB00052089_12; AH-034/32461056; F091532; SR-01000721923; BENZOIC ACID,2-HYDROXY,AMIDE SALICYLAMIDE; Q2496906; SR-01000721923-2; BRD-K81130846-001-02-6; BRD-K81130846-001-12-5; BRD-K81130846-001-17-4; Z68590124; F0451-0020; 2,4-CYCLOHEXADIEN-1-ONE, 6-(AMINOHYDROXYMETHYLENE)-; Salicylamide, United States Pharmacopeia (USP) Reference Standard; InChI=1/C7H7NO2/c8-7(10)5-3-1-2-4-6(5)9/h1-4,9H,(H2,8,10; Salicylamide, Pharmaceutical Secondary Standard; Certified Reference MaterialSynonyms
